PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

NCT02669511

Primary Central Nervous System Lymphoma

COMPLETED PHASE2

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

NCT03127020

Lymphoma Non-Hodgkin Lymphoma

COMPLETED PHASE2

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

NCT02249429

Lymphoma, Malignant

COMPLETED PHASE2

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00452127

Non-Hodgkin's Lymphoma

TERMINATED PHASE1/PHASE2

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05190068

B-Cell Non-Hodgkin's Lymphoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety, and pharmacokinetics effects of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).

The first stage of the study will enroll a minimum of 12 patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL) evaluable for the primary study objective. If during the first stage of the study data emerge that 80 mg p.o. qd is not adequately tolerated or is inefficacious in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL), additional patients may be enrolled in the study to evaluate alternative dosing regimens, either a lower daily dose (eg. 60 mg) or a lower weekly dose with administration on 2 consecutive days followed by 5 days without treatment in 7-day treatment cycles (intermittent dosing schedule A).In all cases data from at least 12 evaluable patients will be required on the selected dosing regimen (daily or weekly) before the decision is made to proceed with this regimen into the second stage of the study.Nine (9) additional patients will be enrolled for the second stage of the study, for a minimum of 21 patients on the selected dosing regimen in total, evaluable for the final primary endpoint analysis.All patients evaluable for the primary endpoint will be followed until disease progression or death.

Secondary objectives, PQR309 treatment safety and pharmacokinetics (PK) will be evaluated in all enrolled patients in both study stages.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Central Nervous System Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PQR309

A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.

Group Type OTHER

PQR309

Intervention Type DRUG

Oral PQR309, 80mg or 60mg daily or intermittent dosing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PQR309

Oral PQR309, 80mg or 60mg daily or intermittent dosing

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥18 years of age.
2. Patient with histologically/cytologically confirmed Primary Central Nervous System Lymphoma (PCNSL)
3. Relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL) demonstrated by cranial MRI.
4. Presence of at least one lesion of bi-dimensionally measurable disease on baseline
5. MRI with a contrast-enhancing tumor of at least 1 cm (10 mm) in the longest diameter.
6. Maximum one prior systemic therapy regimen.
7. If receiving corticosteroids, patients must have been on a stable or decreasing dose of corticosteroids and no more than 8 mg dexamethasone (or equivalent) for at least 5 days prior to date of enrollment.
8. Karnofsky Performance Score (KPS) ≥ 70%.
9. More than 4 weeks from any investigational agent.
10. Adequate haematological, liver and renal function
11. Able and willing to swallow and retain oral medication.
12. Female and male patients of reproductive potential must agree to use effective contraception from screening until 90 days after discontinuing study treatment.
13. Willing and able to sign the informed consent and to comply with the protocol for the duration of the study.

Exclusion Criteria

1. Central Nervous System (CNS) Lymphoma or chronic immunosuppression-associated central nervous system (CNS) lymphoma.
2. Previous allogeneic hematopoietic stem cell transplant (HSCT transplant).
3. Previous whole brain radiotherapy (WBRT)
4. Other concomitant anti-tumor therapy as determined by the study team.
5. Patients unable to undergo contrast-enhanced MRI.
6. Prior treatment with a phosphoinositide -3 kinase (PI3K) inhibitor, Protein Kinase B Inhibitor is known as AKT inhibitor, or mammalian target of rapamycin (mTOR) inhibitor.
7. Patient taking enzyme-inducing anti-epileptic drug (EIAED) \< 7 days of the first dose of PQR309.
8. Patient is taking a drug with a risk to promote QT prolongation and Torsades de Pointes.
9. Patient is currently using herbal preparations or medications. Patient should stop using herbal medications 7 days prior to the first dose of the study drug.
10. Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders.
11. Anxiety ≥ Common Terminology Criteria (CTC) of adverse events (AE) grade 3.
12. Patient has an uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, HIV infection, chronic liver disease.

chronic renal disease, pancreatitis, chronic pulmonary disease, active cardiac disease or cardiac dysfunction, interstitial lung disease, active autoimmune disease, uncontrolled diabetes, neuropsychiatric or social situations that would limit compliance with the study requirements.
13. Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.
14. Concomitant treatment with medicinal products that increase the potential hydrogen (pH), reduce acidity of the upper gastrointestinal tract, including, but not limited to, proton-pump inhibitors (e.g. omeprazole), H2-antagonists (e.g. ranitidine) and antacids. Patients may be enrolled in the study after a washout period sufficient to terminate their effect.
15. Patient has a history of invasive malignancy other than Primary Central Nervous System Lymphoma (PCNSL). Patients are eligible, if they are disease-free for at least 3 years and deemed to be at low risk for recurrence by the investigator. Patients diagnosed with cervical cancer in situ, basal cell or squamous cell carcinoma of the skin and treated within the past 3 years are eligible.
16. Women who are pregnant or breast feeding.
17. Women able to conceive and unwilling to practice an effective method of birth control from screening until 90 days after discontinuing study treatment (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of PQR309).
18. Fasting glucose \> 7.0 mmol/L (126 mg/dL). or HbA1c \> 6.4%.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No